Topiramate in the prevention of migraine: A review of its efficacy, tolerability, and acceptability

Domenico D'Amico, Licia Grazzi, Gennarro Bussone

Research output: Contribution to journalArticlepeer-review

Abstract

This paper reviews the results of placebo-controlled trials on topiramate (TPM) in the prophylaxis of migraine, focusing particularly on efficacy and tolerability of the target dose (100 mg/day). Data from well-conducted trials and analyses of pooled data show that TPM is effective against migraine, confirming the experience of physicians in various countries. High responder rate and good tolerability following slow titration suggest TPM as a first-line option for migraine prophylaxis. Patient acceptability may be enhanced by lack of weight gain, lack of major contraindications, and positive effects on quality of life.

Original languageEnglish
Pages (from-to)261-267
Number of pages7
JournalNeuropsychiatric Disease and Treatment
Volume2
Issue number3
DOIs
Publication statusPublished - 2006

Keywords

  • Acceptability
  • Clinical trials
  • Migraine
  • Prophylaxis
  • Tolerability
  • Topiramate

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Fingerprint

Dive into the research topics of 'Topiramate in the prevention of migraine: A review of its efficacy, tolerability, and acceptability'. Together they form a unique fingerprint.

Cite this